- |||||||||| AAV-CNGA3 / J&J, MeiraGTx, entacingene turiparvovec (AAV-CNGB3) / J&J
Trial completion, Trial completion date, Trial primary completion date, Gene therapy: Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 (clinicaltrials.gov) - May 3, 2024
P1/2, N=34, Completed,
Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Apr 2024 | Trial primary completion date: Jan 2026 --> Apr 2024
- |||||||||| AAV-CNGA3 / J&J, MeiraGTx, entacingene turiparvovec (AAV-CNGB3) / J&J
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Gene therapy: Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 (clinicaltrials.gov) - Jan 14, 2022
P1/2, N=34, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Apr 2024 | Trial primary completion date: Jan 2026 --> Apr 2024 Recruiting --> Active, not recruiting | N=72 --> 34 | Trial completion date: Aug 2024 --> Jan 2026 | Trial primary completion date: Jul 2024 --> Jan 2026
- |||||||||| entacingene turiparvovec (AAV-CNGB3) / J&J
Trial primary completion date, Gene therapy: Gene Therapy for Achromatopsia (CNGB3) (clinicaltrials.gov) - Jul 8, 2020
P1/2, N=23, Completed,
Recruiting --> Active, not recruiting | N=72 --> 34 | Trial completion date: Aug 2024 --> Jan 2026 | Trial primary completion date: Jul 2024 --> Jan 2026 Trial primary completion date: May 2019 --> Oct 2019
- |||||||||| entacingene turiparvovec (AAV-CNGB3) / J&J
Trial completion, Gene therapy: Gene Therapy for Achromatopsia (CNGB3) (clinicaltrials.gov) - Feb 5, 2020
P1/2, N=23, Completed,
Trial primary completion date: May 2019 --> Oct 2019 Active, not recruiting --> Completed
- |||||||||| entacingene turiparvovec (AAV-CNGB3) / J&J
Enrollment closed, Trial completion date, Trial primary completion date, Gene therapy: Gene Therapy for Achromatopsia (CNGB3) (clinicaltrials.gov) - Sep 12, 2019
P1/2, N=23, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Feb 2019 --> Dec 2019 | Trial primary completion date: Feb 2019 --> May 2019
- |||||||||| AAV-CNGA3 / J&J, MeiraGTx, entacingene turiparvovec (AAV-CNGB3) / J&J
Enrollment change, Trial completion date, Trial primary completion date, Gene therapy: Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 (clinicaltrials.gov) - Sep 11, 2019
P1/2, N=72, Recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Feb 2019 --> Dec 2019 | Trial primary completion date: Feb 2019 --> May 2019 N=18 --> 72 | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
- |||||||||| entacingene turiparvovec (AAV-CNGB3) / J&J
Enrollment open, Gene therapy: Gene Therapy for Achromatopsia (CNGB3) (clinicaltrials.gov) - Jan 25, 2017
P1/2, N=18, Recruiting,
N=18 --> 72 | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Jul 2023 --> Jul 2024 Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> Jan 2016 | Not yet recruiting --> Recruiting
|
